Sarah Yahia Moustafa

Dr. Sarah Yahia Moustafa

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2024 in Regenerative Engineering and Translational Medicine
Verified
Journal Article
Closed access
PDF file
EHEman Hany
Eman Hany
AEAhmed A. Emam
Ahmed A. Emam
MEMohamed G. Elbeltagy
Mohamed G. Elbeltagy
MZMahmoud Zakaria
Mahmoud Zakaria
SMSarah Yahia Moustafa
Sarah Yahia Moustafa
RERana El-Qashty
Rana El-Qashty

31 July 2025 in ACS Omega
Verified
Journal Article
Open access
HEHany Abd El-Raheem
Hany Abd El-Raheem
AAAbdullah S. Alawam
Abdullah S. Alawam
HRHassan A. Rudayni
Hassan A. Rudayni
AAAhmed A. Allam
Ahmed A. Allam
RHRabiaa Helim
Rabiaa Helim
WAWaleed Alahmad
Waleed Alahmad
Programmed cell death (apoptosis) safeguards tissue homeostasis, and its dysregulation is a hallmark of cancer, neurodegeneration, and immune disorders. Detecting the earliest biochemical signatures of apoptosis therefore offers a route to sharper diagnosis, real-time therapy monitoring, and data-driven drug discovery. Electrochemical biosensors are uniquely suited to this task because they translate molecular recognition events into electrical signals that are rapid, miniaturizable, and inherently compatible with point-of-care formats. Yet their clinical translation is still limited by three persistent hurdles: (i) selective recognition in protein-rich or highly variable matrices, (ii) long-term signal stability under continuous operation, and (iii) a lack of unified analytical performance standards that hampers cross-platform benchmarking. This critical review charts the most recent material, biochemical, and microelectronic innovations that are beginning to erode these barriers, and identifies emerging strategiesfrom nanostructured electrode interfaces to signal processing that could propel electrochemical apoptosis sensing from proof-of-concept prototypes to reliable bedside tools. By aligning unresolved challenges with promising technological solutions, we aim to guide interdisciplinary efforts toward next-generation diagnostics capable of real-time apoptosis surveillance in complex biological settings.

26 February 2026 in AAPS PharmSciTech
Verified
Journal Article
Open access
PDF file
ARAya A. Refaat
Aya A. Refaat
SMSarah Yahia Moustafa
Sarah Yahia Moustafa
IEIbrahim M. El-Sherbiny
Ibrahim M. El-Sherbiny
Dry eye disease (DED) is a rampant and multifactorial ocular disorder. Conventional ocular drug delivery faces significant challenges due to the complex oc

Verified
Journal Article
Open access
PDF file
ZEZeinab Elmotwaly
Zeinab Elmotwaly
MGMamdooh Ghoneum
Mamdooh Ghoneum
MEMai Alaa El-Dein
Mai Alaa El-Dein
SMSarah Yahia Moustafa
Sarah Yahia Moustafa
IEIbrahim M. El-Sherbiny
Ibrahim M. El-Sherbiny
NENariman K Badr El-Din
Nariman K Badr El-Din
MGN-3 (Biobran), a denatured hemicellulose compound derived from rice bran, possesses potent immunomodulatory and antitumor activity; however, its clinical application is constrained by non-specific tissue distribution, rapid systemic elimination, and poor cellular uptake. To overcome these pharmacological limitations, we engineered MGN-3-loaded lipid nanoparticles (MGN-3.LNPs) formulated with bioactive cinnamon and avocado oils to optimize targeted drug delivery against solid carcinoma. Mice bearing subcutaneous Ehrlich Ascites Carcinoma (EAC) solid tumors received free MGN-3, plain lipid nanoparticles (plain LNPs), or MGN-3.LNPs three times weekly from day 8 to day 26 post-inoculation. The administration of MGN-3.LNPs achieved superior tumor volume suppression (95.00%) compared to free MGN-3 (69.00%) and plain LNPs (63.00%) (p < 0.0001). Mechanistically, MGN-3.LNPs effectively inhibited cancer cell proliferation by suppressing Ki-67 expression while promoting expression shifts that strongly suggest the engagement of mitochondrial-mediated apoptotic signaling, including upregulation of tumor protein p53, Caspase-3, Caspase-9, poly(ADP-ribose) polymerase (PARP), and cytosolic cytochrome c (Cyt c), alongside an elevated Bax/Bcl-2 ratio and reduced 8-hydroxy-2′-deoxyguanosine (8-OHdG) levels. Flow cytometric analysis confirmed that MGN-3.LNPs induced marked G0/G1 cell cycle arrest and promoted sub-G1 apoptotic cell accumulation, which was corroborated by Annexin V/propidium iodide (Annexin V/PI) staining and semiquantitative histopathological evaluation. Furthermore, MGN-3.LNPs downregulated the gene expression of proinflammatory cytokines tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) while restoring redox homeostasis in tumor tissues. Overall, lipidic nanoencapsulation significantly enhances the therapeutic efficacy of MGN-3 against solid tumors through superior nanoscale tissue penetration, prolonged retention, and synergistic lipid–drug bioactivity.

8 June 2026 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
AEAbdelrahman M. Eldaweny
Abdelrahman M. Eldaweny
SMSarah Yahia Moustafa
Sarah Yahia Moustafa
RSRabab Sayed
Rabab Sayed
AAAya I. Abdelaziz
Aya I. Abdelaziz
IEIbrahim M. El-Sherbiny
Ibrahim M. El-Sherbiny

1 July 2026 in Journal of Drug Delivery Science and Technology
Verified
Journal Article
Closed access
AAAbdullah T. Agamey
Abdullah T. Agamey
SMSarah Yahia Moustafa
Sarah Yahia Moustafa
IEIbrahim M. El-Sherbiny
Ibrahim M. El-Sherbiny